Psychosis Market Report 2026

The psychosis market size has grown strongly in recent years. It will grow from $10.46 billion in 2025 to $11.06 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing diagnosis of schizophrenia and related disorders, expansion of hospital-based psychiatric care, wider use of antipsychotic medications, growing mental health awareness, availability of specialized mental health clinics.

The psychosis market size is expected to see strong growth in the next few years. It will grow to $13.7 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing investment in novel antipsychotic drug development, rising focus on early-stage psychosis management, expansion of community-based mental health services, growing adoption of digital therapeutics, increasing demand for long-term disease management. Major trends in the forecast period include increasing use of long-acting injectable antipsychotics, rising adoption of early intervention programs, growing focus on integrated care models, expansion of digital monitoring tools for psychosis, enhanced emphasis on personalized treatment plans.

The growing number of mental health conditions is expected to drive the expansion of the psychosis market in the coming years. Mental health conditions are disorders that affect an individual’s mood, thinking patterns, behavior, and overall psychological well-being. The rise in mental health conditions is attributed to factors such as increasing stress levels, lifestyle changes, social isolation, economic pressures, and genetic susceptibility. Treatment for psychosis supports individuals with mental health conditions through early identification, medical management, and specialized therapeutic approaches, resulting in greater use of antipsychotic medications and supportive therapies. For example, in May 2024, according to the American Psychiatric Association, a US-based professional organization for psychiatrists, 43% of adults reported experiencing higher anxiety levels compared to the previous year, up from 37% in 2023 and 32% in 2022. Therefore, the rising prevalence of mental health conditions is contributing to the growth of the psychosis market.

Major organizations operating in the psychosis market are increasingly focusing on advanced patient-voice initiatives and data collection programs to improve service design, guide policy development, and strengthen recovery-oriented care models. Patient-voice initiatives allow individuals with lived experience and their families to directly communicate their needs, challenges, and outcomes through structured surveys and research efforts, supporting evidence-based advocacy and more effective healthcare system reforms. For instance, in November 2025, Shine, an Ireland-based national mental health organization, in collaboration with Mental Health Reform, an Irish mental health coalition, and the HSE National Clinical Programme for Early Intervention in Psychosis, launched the 2025 National Survey of the Experiences of People Living with Psychosis. This initiative gathers firsthand insights from individuals with psychosis and their families to better understand access to care, identify systemic gaps and stigma, and inform improvements in national policy, investment in specialized early intervention services, and expansion of community-based and crisis support programs.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition is intended to strengthen Bristol Myers Squibb’s neuroscience portfolio by adding KarXT, a novel antipsychotic therapy, and expanding its development pipeline with potential treatments for schizophrenia, Alzheimer’s disease, and other mental health conditions. Karuna Therapeutics is a US-based biopharmaceutical company specializing in the development of psychosis therapies.

Major companies operating in the psychosis market are Pfizer Inc., Johnson And Johnson, AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Inc., Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Dr Reddys Laboratories Ltd., Lundbeck AS, Gedeon Richter, Alkermes, Supernus Pharmaceuticals, Acadia Pharmaceuticals, Mapi Pharma, Astellas Pharma Inc., Newron Pharmaceuticals SpA, BioXcel Therapeutics, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Zydus Lifesciences Ltd.

North America was the largest region in the psychosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the psychosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the psychosis market by increasing costs of imported pharmaceutical ingredients, injectable drug delivery systems, diagnostic imaging equipment, and digital health tools. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported medications and technologies, while Asia-Pacific faces higher production costs for generic antipsychotics. These tariffs are contributing to higher treatment expenses. At the same time, they are encouraging domestic drug manufacturing, localized formulation development, and regional clinical research investments.

The psychosis market research report is one of a series of new reports that provides psychosis market statistics, including psychosis industry global market size, regional shares, competitors with a psychosis market share, detailed psychosis market segments, market trends and opportunities, and any further data you may need to thrive in the psychosis industry. This psychosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Psychosis is a mental health condition in which individuals experience a loss of contact with reality, often marked by hallucinations, delusions, and disorganized thinking. It is considered a symptom associated with several mental illnesses rather than a standalone disorder. Early diagnosis can improve treatment outcomes, and appropriate management through medication, therapy, and supportive care can help individuals achieve greater stability.

The primary product types used in the treatment of psychosis include tablets, capsules, and injections. Tablets are a commonly used oral dosage form, offering convenience and accurate dosing to maintain consistent therapeutic drug levels. Psychosis is associated with various disease types, including schizophrenia, bipolar disorder, unipolar depression, dementia, and others. These products are distributed through both online and offline channels and are used across multiple end users, such as hospitals, healthcare clinics, specialty clinics, and other care settings.

The psychosis market consists of sales of transdermal patches, nasal sprays, intravenous (IV) infusions, long-acting injectable (LAI) implants, and inhalable formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.